The BioMonitor is a ‘subcutaneous implantable leadless cardiac monitor for long-term continuous remote monitoring of patients with arrhythmias such as AF, bradycardia, sudden rate drop, asystole and tachycardia,’ the manufacturer Biotronik reports.
Sensitivity and specificity are essential to detect arrhythmias such as AF. Thus the firm developed ClearSense Technology which has, it explains, ‘a unique three-vector signal detection that produces highly precise and reliable arrhythmia monitoring. ‘The technology records three ECG channels converting them to one high quality ECG input signal to clearly distinguish, on a beat-to-beat basis, between a genuine signal and other artifacts, such as myopotentials due to body muscle contractions. This innovative technology allows for optimal arrhythmia detection independent of the device’s implant orientation within the body and provides longevity of 6.4 years’.
The home monitoring system provides daily remote data transfer without patient interaction and its ‘traffic light system’ streamlines monitoring by highlighting the most relevant information and providing accurate data for physicians to monitor and manage their patients effectively.
The world’s first physicians to implant the BioMonitor to measure HF in patients are Professors Gerhard Hindricks, at the Electrophysiology Department, Leipzig University Heart Centre, Wilhelm Haverkamp, at the Cardiology Department, Charité Campus Virchow, Humboldt University Berlin, and Dietmar Bänsch, at the Cardiology and Rhythmology Department, Rostock University Hospital. Prof. Haverkamp observed: ‘BioMonitor, with its ClearSense technology, and Biotronik Home Monitoring offer the optimal combination of reliability and efficiency.’ Prof. Bänsch also commented: ‘BioMonitor supports physicians in every step of arrhythmia management, from diagnosis via monitoring to individualised therapy,’